Shukla Pooja, Singh R K
Academy for Scientific and Innovative Research, New Delhi, India; Molecular Hematological Facility, Division of Toxicology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Pharmacogn Mag. 2015 Oct;11(Suppl 3):S380-7. doi: 10.4103/0973-1296.168983.
High regenerative and proliferative capacity of blood and its components renders it to be at higher risk of adverse drug reactions (ADRs) which are manifested in several treatment regimens against various ailments such as cancers, viral diseases, and several metabolic disorders.
It is prudent to come up with some therapeutic entity that can prevent this damage and protects the blood from these ADRs.
We examined protective effects of Plumbago zeylanica (PZ) and its active constituent plumbagin (PL) on Sprague Dawley (SD) rats using a phenylhydrazine (Phz) induced hematotoxicity model. Hemoglobin (Hgb), red blood cells (RBCs), mean corpuscular volume, mean corpuscular Hgb (MCH), MCH concentration (MCHC), leukocytes and platelets were studied. Anti-oxidant enzymes superoxide dismutases 2 and 3 (SODs) and nuclear erythroid 2 p45-related factor 1 and 2 (Nfer-1 and 2) were also studied using quantitative real-time polymerase chain reaction (PCR).
In Phz treated rats, the positive hematotoxic response was obtained in terms of deviated endpoints of blood indices. In PLtreated groups protective response was obtained in terms of normal endpoints of blood indices. In PCR studies, we observed the similar trend. Thus, it can be postulated that PL exerts its protective effects via modulation of anti-oxidant enzymes.
The study proves that PL can be employed against combatting the ADRs associated with several therapeutic treatment regimens. Similar studies employing such pharmacological entities and their combinations may further prove to be effective against ADRs, especially in the context of blood cells.
Hematotoxicity is generally encountered in various therapeutic regimens as ADRs (Adverse Drug Reactions). Plumbagin, an active constituent of plant Plumbago zeylanica is tested for its anti-hematotoxic potential in Phenylhydrazine induced hematotoxicity model in Sprague dawley rats. In vivo, in-vitro and molecular studies confirmed the peremptory actions of PL. It was revealed in our studies that the anti-hematotoxic actions of Plumbagin are due to its capacity to modulate anti-oxidant enzyme system.
血液及其成分具有较高的再生和增殖能力,这使其在针对多种疾病(如癌症、病毒性疾病和多种代谢紊乱)的几种治疗方案中出现药物不良反应(ADR)的风险更高。
提出某种治疗实体以预防这种损害并保护血液免受这些ADR影响是明智的。
我们使用苯肼(Phz)诱导的血液毒性模型,研究了白花丹(PZ)及其活性成分白花丹醌(PL)对Sprague Dawley(SD)大鼠的保护作用。研究了血红蛋白(Hgb)、红细胞(RBC)、平均红细胞体积、平均红细胞血红蛋白(MCH)、MCH浓度(MCHC)、白细胞和血小板。还使用定量实时聚合酶链反应(PCR)研究了抗氧化酶超氧化物歧化酶2和3(SODs)以及核红细胞2 p45相关因子1和2(Nfer-1和2)。
在Phz处理的大鼠中,血液指标的终点出现偏差,呈现出阳性血液毒性反应。在PL处理组中,血液指标的终点正常,呈现出保护反应。在PCR研究中,我们观察到了类似的趋势。因此,可以推测PL通过调节抗氧化酶发挥其保护作用。
该研究证明PL可用于对抗与多种治疗方案相关的ADR。采用此类药理实体及其组合的类似研究可能进一步证明对ADR有效,尤其是在血细胞方面。
血液毒性通常在各种治疗方案中作为ADR(药物不良反应)出现。在Sprague dawley大鼠的苯肼诱导血液毒性模型中,测试了植物白花丹的活性成分白花丹醌的抗血液毒性潜力。体内、体外和分子研究证实了PL的决定性作用。我们的研究表明,白花丹醌的抗血液毒性作用归因于其调节抗氧化酶系统的能力。